Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Addex completes the first part of a two-part phase I ADX-48621 trial

Oct. 16, 2008

Akorn launches Akten Gel 3.5% as a topical ocular anesthetic

Oct. 16, 2008

MJFF awards USD 2 million grant to research projects on cognitive deficits in PD

Oct. 16, 2008

Experiments with caprospinol reveal potentially useful effects against Alzheimer's disease

Oct. 16, 2008

Neurogen reports results from phase II trials of aplindore in RLS and PD

Oct. 15, 2008

Acura and King present top-line results for Acurox in abuse liability

Oct. 15, 2008

FDA agrees with Neurobiological to consolidate Viprinex phase III trials

Oct. 14, 2008

New treatment options for AD and other cognition disorders described in recent Roche patent

Oct. 14, 2008

Archimedes reports positive results from phase III study of NasalFent in cancer pain

Oct. 13, 2008

ReGen launches Colostrinin under the name Cognase in Cyprus

Oct. 13, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....